<DOC>
	<DOCNO>NCT01327638</DOCNO>
	<brief_summary>The study intend provide additional post-marketing safety data regard use etoricoxib indication ankylose spondylitis .</brief_summary>
	<brief_title>Safety Etoricoxib ( MK-0663 ) Patients With Spondyloarthropathy ( SpA ) /Ankylosing Spondylitis ( AS ) Sweden ( EP07013.013.11.082 )</brief_title>
	<detailed_description>The specific project objectives : 1 ) Describe characteristic Swedish patient inflammatory SpA/AS ; 2 ) Describe use etoricoxib cyclooxygenase-2 ( COX-2 inhibitor ) /non-selective nonsteroidal anti-inflammatory drug ( nsNSAIDs ) Swedish patient SpA/AS ; 3 ) Estimate compare rate clinical outcome special interest ( gastrointestinal , renovascular , cardiovascular cerebrovascular ) use etoricoxib COX-2 inhibitors/nsNSAIDs Swedish patient SpA/AS . Comparisons clinical outcome among drug interest make descriptive comparison point estimate incidence rate associate 95 % confidence interval ( CIs ) , use clinical epidemiological judgment light limitation observational study . No formal statistical significance test perform purpose comparison .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>Participant attend outpatient clinic 20012010 . Participant register International Classification diseases ( ICD , Version 10 ) code correspond SpA/AS AS .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>